Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines

Int J Hematol. 2007 Dec;86(5):429-37. doi: 10.1007/BF02984001.

Abstract

Our previous studies demonstrated that a low concentration of 2-methoxyestradiol (2ME2) could induce the differentiation of myeloma cell lines and CD138+ primary myeloma cells from myeloma patients and up-regulate the expression of messenger RNA (mRNA) and protein for the gene encoding X-box binding protein 1 (Xbp-1) in myeloma cell lines. In the present study, we used phosphorothioated antisense oligodeoxynucleotides (ASODN) to investigate the roles and interactions of transcription factors Xbp-1, B-lymphocyte induced maturation protein 1 (Blimp-1), and PAX-5-encoded B-cell-specific activator protein (BSAP), which are thought to be involved in the regulation of B-lymphocytic or plasmacytic differentiation. Blimp-1 ASODN and Xbp-1 ASODN clearly inhibited myeloma cell differentiation and significantly partially inhibited the differentiation effects induced by 2ME2 at low concentration, whereas PAX-5 ASODN clearly induced myeloma cell differentiation and significantly enhanced 2ME2-induced differentiation effects. Moreover, after incubation with Blimp-1 ASODN, the level of Xbp-1 mRNA clearly declined, whereas the level of PAX-5 mRNA significantly increased in myeloma cells. These results demonstrate that transcription factors Xbp-1, Blimp-1, and PAX-5-encoded BSAP play important roles in the regulation of plasmacytic differentiation and exert their effects on differentiation induced by low 2ME2 concentrations. Our primary study provided the rationale for a promising strategy-the future application of transcription-factor ASODN for clinical patients.

MeSH terms

  • 2-Methoxyestradiol
  • Cell Differentiation / drug effects*
  • Cell Differentiation / genetics
  • Cell Line, Tumor
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism*
  • Dose-Response Relationship, Drug
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics
  • Multiple Myeloma / metabolism*
  • Multiple Myeloma / pathology
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism*
  • Oligodeoxyribonucleotides, Antisense / genetics
  • Oligodeoxyribonucleotides, Antisense / pharmacology
  • Oligodeoxyribonucleotides, Antisense / therapeutic use
  • PAX5 Transcription Factor / antagonists & inhibitors
  • PAX5 Transcription Factor / genetics
  • PAX5 Transcription Factor / metabolism*
  • Plasma Cells / metabolism*
  • Plasma Cells / pathology
  • Positive Regulatory Domain I-Binding Factor 1
  • Regulatory Factor X Transcription Factors
  • Repressor Proteins / antagonists & inhibitors
  • Repressor Proteins / genetics
  • Repressor Proteins / metabolism*
  • Syndecan-1 / genetics
  • Syndecan-1 / metabolism
  • Transcription Factors / antagonists & inhibitors
  • Transcription Factors / genetics
  • Transcription Factors / metabolism*
  • Tubulin Modulators / pharmacology*
  • Up-Regulation / drug effects
  • X-Box Binding Protein 1

Substances

  • DNA-Binding Proteins
  • Nuclear Proteins
  • Oligodeoxyribonucleotides, Antisense
  • PAX5 Transcription Factor
  • PAX5 protein, human
  • Regulatory Factor X Transcription Factors
  • Repressor Proteins
  • SDC1 protein, human
  • Syndecan-1
  • Transcription Factors
  • Tubulin Modulators
  • X-Box Binding Protein 1
  • XBP1 protein, human
  • PRDM1 protein, human
  • Estradiol
  • 2-Methoxyestradiol
  • Positive Regulatory Domain I-Binding Factor 1